Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Laser-guided rescue: endoscopic removal of complex esophageal foreign bodies.
Journal: Endoscopy
Published: August 08, 2025
Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera® in low-tumor-burden follicular lymphoma: the FLINTER study.
Journal: Therapeutic advances in medical oncology
Published: July 09, 2024
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study.
Journal: Arthritis research & therapy
Published: July 09, 2024
Comparison of Efficacy and Safety of a Bevacizumab Biosimilar, in Combination with Chemotherapies, in Nonresectable Metastatic Colorectal Cancer and in Advanced Nonsquamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study.
Journal: South Asian journal of cancer
Published: May 09, 2024
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial.
Journal: JCO global oncology
Published: January 18, 2024
Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era.
Journal: Frontiers in oncology
Published: June 27, 2023
Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity.
Journal: CPT: pharmacometrics & systems pharmacology
Published: May 02, 2022
A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin® (EU) in healthy adult males.
Journal: The Indian journal of medical research
Published: February 10, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026